AbGn-168H Neihulizumab
100
100
100
0
0
Phase II
Phase II POC ready and to bridge with s.c. version.
100
100
30
0
0
Phase II
Phase II Inflammatory T Cell Control Antibody for TNF-i and/or Entyvio or JAK-i Refractory Ulcerative Colitis, Phase ll ongoing.
100
50
0
0
0
Phase I
Phase I Inflammatory T Cell Control Antibody for Steroid Refractory-Acute Graft versus Host Disease (GvHD) , Phase 1 ongoing (in patients).
AbGn-268 Leiolizumab
80
0
0
0
0
Preclinical
Preclinical Potency improved version of AbGn-168H for Chronic Inflammatory Disease
AbGn-107
100
50
0
0
0
Phase I
Phase I Antibody Drug Conjugate for Gastrointestinal Cancer, currently in cohort expansion phase of clinical study for efficacy assessment in advanced Gastric Cancer, Pancreatic Cancer, Biliary Cancer and Colorectal Cancer patients
AbGn-207
50
0
0
0
0
Preclinical
Preclinical CAR-T for Antigen Positive Cancer
Discover, Develop and Deliver
Innovative Therapies That Make an Impact
b2/20180914134948v4ecbwM755.png)
b2/20180914134949966ao04Yh7.png)
A proof-of-principle study to test the efficacy and safety of Neihulizumab in patients with moderate to severe active ulcerative colitis and who have failed or are intolerant to anti-TNFα and/or anti-integrin therapy
b2/201809141349509ugarxwbm8.png)
b2/201809141349508f0tv9ZK910.png)
Study evaluating the safety, signs of efficacy, pharmacokinetics, receptor occupancy and pharmacodynamics biomarkers of Neihulizumab in patients with steroid-refractory acute GvHD
b2/20180914134950ewk4tfHeH11.png)
b2/20180914134951e1dsx2ihp12.png)
This study is to define the safety profile and to determine the maximum tolerated dose (MTD) and preliminary efficacy of AbGn-107
b2/20180914134951f2zzjoyyL13.png)
b2/20180914134951yf3pllMYq14.png)
This study is to define the safety profile and to determine the maximum tolerated dose (MTD) and preliminary efficacy of AbGn-107
b2/20180914134951r1ahteBHY15.png)
b2/20180914134952p7kr3j02M16.png)
This study is to define the safety profile and to determine the maximum tolerated dose (MTD) and preliminary efficacy of AbGn-107
AltruBio Inc. moves forward with clinical development of Neihulizumab in Steroid-Refractory Acute Graft-versus-Host Disease after encouraging Phase 1a results
AltruBio Inc. presented AbGn-107 Phase 1a chemo-refractory GI cancer results at ASCO-GI 2020
AltruBio’s presentation on Neihulizumab Phase 2a Ulcerative colitis results selected as Poster of Distinction at Digestive Disease Week (DDW) 2020
2F, No. 36, Lane. 358, Juikuang Road
Neihu, Taipei, Taiwan 11492
Tel: (886)-2-2627-2707
E-mail: info@altrubio.com
555 Twin Dolphin Drive, Suite #310,
Redwood City, CA94065 U.S.A.
Tel: (650)453-3462
E-mail: info@altrubio.com
Kingsfordweg 103, 1043 GP Amsterdam
The Netherlands
Tel: +31 (0)88-1009333
E-mail: abgcoop@abgenomics.nl
